| Literature DB >> 23977186 |
Liulin Chen1, Junming Zhu, Yuhong Li, Jie Lu, Li Gao, Huibi Xu, Mingwen Fan, Xiangliang Yang.
Abstract
The design of optimized nanoparticles offers a promising stEntities:
Mesh:
Substances:
Year: 2013 PMID: 23977186 PMCID: PMC3748075 DOI: 10.1371/journal.pone.0071953
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Gel retardation analysis of CS-based NPs using plasmid pGJA-p/VAX as the DNA model.
(A) CS/DNA, at different N/P ratios. (B) AL/CS/DNA, at different lipid/DNA (w/w) ratios with a fixed N/P ratio of 7. (C) AL/CS/DNA, treated with DNase I at the lipid/DNA (w/w) ratio of 3 with a fixed N/P ratio of 7. lane 1: DNA ladder; lane 2: pGJA-p/VAX; lane 3: pGJA-p/VAX+DNase I (50 U/ml); lane 4: AL/CS/DNA; lane 5: AL/CS/DNA+DNase I (50 U/ml); lane 6: AL/CS/DNA+DNase I (100 U/ml); lane 7: AL/CS/DNA+DNase I (200 U/ml); lane 8: PEI/DNA+DNase I (200 U/ml); lane 9: PEI/DNA.
Physicochemical characteristics of CS/DNA and AL/CS/DNA.
| Formulations (N/P, lipid/DNA) | Size (nm) | PDI | Zeta potential (mV) | Encapsulation efficiency (%) |
| CS/DNA (7, 0) | 323.5±20.3 | 0.259±0.014 | 4.8±1.3 | 96.46±2.41 |
| AL/CS/DNA (7, 1) | 312.7±14.7 | 0.205±0.082 | 4.5±0.7 | 95.32±0.48 |
| AL/CS/DNA (7, 2) | 320.1±12.3 | 0.214±0.054 | 8.1±0.8 | 97.34±1.02 |
| AL/CS/DNA (7, 3) | 319.5±16.9 | 0.134±0.027 | 6.7±0.3 | 96.36±1.35 |
| AL/CS/DNA (7, 4) | 498.5±28.9 | 0.125±0.032 | 2.5±0.8 | 95.26±0.45 |
| FITC-CS/DNA (7, 0) | 340.5±27.4 | 0.237±0.044 | 4.4±0.5 | 99.42±0.11 |
| AL/FITC-CS/DNA (7, 3) | 338.5±12.1 | 0.101±0.025 | 7.7±0.2 | 98.24±0.21 |
| Cy5.5-CS/DNA (7, 0) | 328.6±15.6 | 0.233±0.036 | 4.0±1.1 | 96.64±0.25 |
| AL/Cy5.5-CS/DNA (7, 3) | 315.4±18.1 | 0.128±0.035 | 6.1±1.6 | 96.24±0.34 |
Particle size, polydispersity index (PDI), zeta potential and encapsulation efficiency of tested NPs with different N/P ratios and lipid/DNA ratios under pH 6.4 (n = 3).
Figure 2Transgene expression by HEK 293 cells in vitro using CS/DNA, AL/CS/DNA and PEI/DNA NPs.
(A) CS/Luc, at different N/P ratios with fixed 1 µg plasmid pcDNA3.0-Rluc/well and fixed transfection medium pH of 6.4; (B) AL/CS/Luc, at different lipid/DNA ratios (0, 1, 2, 3, 4, w/w) with fixed N/P ratio of 7 and fixed transfection medium pH of 6.4 and 1 µg plasmid pcDNA3.0-Rluc/well. PEI/Luc NPs at N/P ratio of 10 were used as the positive control; (C) Transfection images of CS/GFP and AL/CS/GFP NPs with different N/P ratios and lipid/DNA ratios using GFP as a report gene. The relative light units (RLU) were normalized to the protein content of each sample. **p<0.01 Mean ± SD (n = 4–6).
Figure 3Characterization of the CS/DNA and AL/CS/DNA NPs.
(A) Size and zeta potential of CS/DNA and AL/CS/DNA at pH 7.4, 7.1, 6.8 and 6.4. (B) TEM images of the CS/DNA at pH 6.4; (C) TEM images of the AL/CS/DNA at pH 6.4. (D) TEM images of the AL/CS/DNA at pH 7.4; (E) Local amplification of (D); (F) Release profile of DNA from AL/CS/DNA and CS/DNA in PBS (pH 6.4 or 7.4) at 37°C. Mean ± SD (n = 3).
Figure 4Analysis of nasal residence time and mucin adsorption ability of CS-based NPs.
(A) Fluorescence images of nasal clearance of Cy5.5-CS/DNA and AL/Cy5.5-CS/DNA after i.n. administration. (B) Clearance derived from spectra. Fluorescence at t = 0 was set as 100%. (C) Adsorption of mucin on the CS/DNA and AL/CS/DNA. Formulations were prepared at pH 6.4; **p<0.01 Mean ± SD (n = 4).
Figure 5Representative Z-scan images of the FITC-CS/DNA and AL/FITC-CS/DNA treated rat nasal mucosa.
(A) FITC-CS/DNA, treated for 2 h. (B) AL/FITC-CS/DNA, treated for 2 h. Both the 24 images were from the apical side to depth of 17.6 µm beneath mucosa and in successive steps with 0.8 µm apart. Images of the x, z and y, z sections captured in the depth of 8.8 µm inside mucosa from the apical side were shown below. Red arrow represents FITC-CS/DNA; Blue arrow represents AL/FITC-CS/DNA.
Figure 6TEER decrease and intracellular uptake on Caco-2 cells after CS/DNA and AL/CS/DNA treatment.
(A) TEER decrease of Caco-2 cell monolayer after 1 h exposure to the above formulations. (B) Percentages of intracellular uptake of test formulations after administration for 2 h. (C) Flow cytometry pictures are representatives of each group. (n = 3) *p<0.05, **p<0.01.
Figure 7Antibody levels of saliva and serum collected from mice immunized with different formulations and routes.
(A) Specific anti-PAc salivary IgA levels (ng/ml); (B) Specific anti-PAc serum IgG levels (µg/ml). Samples were collected at weeks 2, 4, 6, 8 and 12. Compared with the AL/CS/DNA (i.n.) group, *p<0.05, **p<0.01; Mean ± SD (n = 10).
Figure 8MTT results of the RAW 264.7 cells viability after treating with indicated concentrations of previously prepared PEI/DNA, CS/DNA and AL/CS/DNA NPs.
Mean ± SD (n = 4).